Natriuretic peptides in the diagnosis of heart disease - First amongst equals?

International Journal of Cardiology

Volumn 84, Issue 2-3, 2002, Pages 107-113

  Daly, C ^a   Fox, K ^a   Henein, M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Diagnostic markers; Heart failure; Natriuretic peptides

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARDIOTROPHIN 1; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; PROSTAGLANDIN;

ANGINA PECTORIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; KIDNEY FAILURE; MEASUREMENT; MEDICAL ASSESSMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; REVIEW; SIGNAL TRANSDUCTION; TECHNIQUE;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 0036071541     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00143-2     Document Type: Editorial

References (80)

1. Hormones and haemodynamics in heart failure
2. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
3. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular wall stress in patients with aortic stenosis
4. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension
5. Atrial natriuretic peptide elevation in congestive heart failure in the human
6. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
7. Biochemical detection of left-ventricular systolic dysfunction
8. Electron microscopy of the heart
9. The possible role of cardiac stretch receptors in the induction of changes in urine flow
10. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract
11. A new natriuretic peptide in porcine brain
12. BNP as a novel cardiac hormone in humans
13. CNP: A new member of the natriuretic peptide family identified in porcine brain
14. Natriuretic peptides: Physiology, therapeutic potential and risk stratification in ischaemic heart disease
15. Atrial natriuretic peptide causes pre-glomerular vasodilation and post glomerular vasoconstriction in rat kidney
16. Effect of atriopeptin III on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus
17. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease
18. Effect of BNP on renal haemodynamics, tubular function and vasoactive hormones in humans
19. Renal and systemic haemodynamic effects of synthetic atrial natriuretic peptide in the anaesthetised rat
20. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans
21. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubule sodium and water reabsorption
22. Atrial and brain natriuretic peptides inhibit the endothelin 1 secretory response to angiotensin II in porcine aorta
23. Vagal C-fibre blockade abolishes sympathetic inhibition by atrial natriuretic factor
24. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii
25. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts
26. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes
27. Effect of endogenous natriuretic peptide system on ventricular and coronary system in the failing heart
28. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent chronic renal failure
29. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
30. Atrial and brain natriuretic peptides: A dual natriuretic peptide system potentially involved in circulatory homeostasis
31. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure
32. The influence of supine relaxation on blood pressure, heart rate and atrial natriuretic peptide in normal subjects
33. The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure
34. Measurement and significance of circulating natriuretic peptides in cardiovascular disease
35. Phenylephrine, endothelin, prostaglandin F2alpha′ and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro
36. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy
37. Cardiotrophin-1 a new agonist for a gp130 signalling pathway, stimulates brain natriuretic peptide (BNP) secretion more abundantly than endothelin-1 (ET-1)
38. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
39. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study
40. Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: A prospective study
41. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin I
42. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
43. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
44. Comparison of atrial natriuretic peptide, B type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
45. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
46. Prolonged stability of BNP: Importance for non-invasive assessment of cardiac function in clinical practice
47. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
48. Plasma natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
49. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy
50. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction
51. Plasma brain natriuretic peptide an important predictor of cardiovasular mortality in acute heart failure
52. Diastolic dysfunction and natriuretic peptides in systolic heart failure
53. Increased levels of brain natriuretic peptide in patients with isolated diastolic dysfunction
54. Increased levels of brain natriuretic peptide in patients with acute myocardial infarction
55. Plasma BNP as an indicator for ACEI after myocardial infarction
56. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
57. Plasma brain natriuretic peptide as a prognostic indicator in patients with pulmonary hypertension
58. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale
59. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease
60. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy
61. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis
62. Plasma BNP concentrations in patients with chronic mitral valve regurgitation
63. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty
64. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina
65. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation
66. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines
67. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomised comparison of the haemodynamic and neuroendocrine effects of tailored versus empirical therapy
68. High levels of brain natriuretic peptide and interleukin-6 after optimised treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
69. Radioimmunoassay for alpha-human and rat atrial natriuretic polypeptide
70. Brain natriuretic peptide-like immunoreactivity is present in human plasma
71. Measurement and importance of plasma brain natriuretic peptide and related peptides
72. Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma
73. Circulating levels of natriuretic peptides (ANP and BNP) measured by highly sensitive immunoradiometric assays in normal subjects and in patients with different degrees of heart failure
74. Analytical agreement and clinical correlates of plasma brain natriuretic peptide measured by three immunoassays in patients with heart failure
75. N-terminal atrial natriuretic peptide in human plasma: Investigation of plasma levels and molecular circulating form(s) using radio-immunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126)
76. An immunoluminometric assay for N terminal pro-brain natriuretic peptide: Development of a test for left ventricular dysfunction
77. Enzymimmunoassays fur pro-BNP fragmente (8-29) und (32-57)
78. Plasma brain natriuretic peptide measured by fully-automated immuno-assay and by immunoradiometric assay compared
79. Validating aminoterminal BNP assays: A word of caution
80. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide and related peptides) in clinical practice: The need for a new generation of immunoassay methods